Strengths
- CB Insights lists Neko Health as a $1.8B private unicorn.
- Neko Health publicly markets an active product/service platform.
- Neko Health has public customer, buyer, partner or demand-channel signals.
Diligence report
Neko Health
Neko Health Startup Diligence Report
Proceed only to confirmatory diligence. A thesis for Neko Health depends on proving durable revenue or utilization growth, retention, margin, defensible product value, compliance posture, leadership depth and financing terms beyond public-list valuation evidence.
Company profile
Neko Health Startup Diligence Report
Neko Health appears to be an active uncovered private unicorn based on the fetched CB Insights list and active public company/product materials. Public evidence supports status screening and product/GTM presence, but investment-grade diligence remains unresolved because financials, customer quality, contracts, legal/regulatory posture, cap table and personnel data are private.
- Website
- www.nekohealth.com
- Sector
- Preventive health checks, full-body scanning, clinical operations, and AI-enabled health data analysis
- Geography
- Sweden and United Kingdom with announced international expansion signals
- Stage
- Private unicorn / growth-stage healthcare and life sciences company
- Known aliases
- Neko, HJN Sverige AB (CB Insights profile slug)
- Report version
- 1.0
- Timezone
- UTC
Executive summary
Risks
- Clinical, medical-device, privacy and advertising compliance
- Clinic utilization, unit economics and repeat-rate uncertainty
- Expansion execution and medical staffing dependency
Gaps
- Audited financial statements, KPI pack and cash/debt schedule
- Fully diluted cap table, preferences, debt and investor rights
- Top customer or clinic/user cohort revenue, utilization, renewal and satisfaction data
- Sales productivity, funnel conversion, CAC, payback and budget data
- Roadmap, technical benchmarks, security/quality artifacts and incident history
Risk register
R-006: Legal, privacy and regulatory exposure is under-diligenced publicly
Healthcare delivery creates material privacy, medical-device, clinical-safety, advertising, recordkeeping and jurisdictional licensing exposure.
Diligence request: Have counsel review regulatory correspondence, contracts, privacy/security controls, insurance, IP assignments, litigation and compliance history.
R-001: Financial quality and valuation support are private
Valuation and a public scan price are visible, but clinic utilization, gross margin, payback, repeat rate, medical staffing cost and cash burn are not public.
Diligence request: Obtain audited financials, KPI pack, quality-of-revenue analysis, forecast model, cash/debt schedule and board-approved budget.
R-003: Customer concentration, retention and satisfaction are not public
Consumer demand signals do not disclose waitlists, conversion, repeat scans, refund rates, complaints, clinical outcomes or cohort retention.
Diligence request: Request top-account/customer cohorts, renewal/churn, NRR, utilization, support tickets, complaints and reference calls.
R-002: Cap table, preferences and financing terms are unverified
Public unicorn-list valuation does not reveal liquidation preferences, option pool, warrants, debt, secondary transactions, investor rights or current share count.
Diligence request: Request fully diluted cap table, financing documents, investor consents, SAFEs/notes/debt and waterfall analysis.
R-004: Competitive intensity may compress growth or pricing
Preventive health scanning competes with imaging startups, private clinics and public health pathways while facing clinical-evidence scrutiny.
Diligence request: Run win/loss calls, pricing benchmarks, competitive feature audit and buyer-reference interviews.
R-005: Product and technical claims require independent validation
The model depends on sensor accuracy, AI interpretation, clinical workflows, false positives/negatives, patient experience and doctor availability.
Diligence request: Commission product, security, reliability, architecture, roadmap and benchmark reviews.
R-007: Team depth, retention and compensation are not public
Founder brand is strong, but current operating org, clinical governance, staffing depth and turnover are not public.
Diligence request: Request org chart, management bios, HRIS export, attrition, compensation, option grants, engagement survey and key-person plans.
R-008: Operational dependencies may constrain scale
Clinic expansion depends on leases, equipment uptime, medical staffing, local regulatory approvals and supply-chain/service support.
Diligence request: Review supplier contracts, infrastructure dependencies, SLAs, incident history, business continuity and concentration risk.
01Financial Information
Neko Health's public valuation/status is supported by CB Insights, but financial statements, cap table, debt, cash runway, unit economics and forecast assumptions remain private.
I.A Annual and quarterly financial information for the past three years
not publicly verifiable confidence: low
Public sources do not disclose audited annual/quarterly financial statements, management accounts, budget-to-actuals, backlog, AR aging or product/geography gross profit.
Evidence gaps
- Audited statements, KPI packs and accounting policies are private.
Hidden risks
- R-001 remains open until private diligence closes this section.
Follow-up questions
- Provide audited financial statements, management reports, revenue bridge, backlog and AR aging.
| metric | public signal | verification status | diligence request |
|---|---|---|---|
| Revenue / ARR | No audited revenue or ARR disclosed in fetched public sources. | not_publicly_verifiable | Audited revenue, ARR bridge, bookings, deferred revenue and revenue-recognition memo. |
| Pricing / monetization | Public homepage pricing discloses a GBP 299 scan price, but utilization, margin, payor mix, refunds and expansion economics are not public. | partially_verified | Contracted pricing, discounts, gross margin, CAC/payback and cohort data. |
| Cash burn / runway | Not disclosed publicly. | not_publicly_verifiable | Cash, debt, monthly burn, forecast scenarios and financing plan. |
I.B Financial Projections
partially verified confidence: medium
A public valuation/commercialization anchor exists, but projections, assumptions and budget-to-actuals are private.
Evidence gaps
- Forecast model, scenario assumptions and external financing assumptions are private.
Hidden risks
- R-001 remains open until private diligence closes this section.
Follow-up questions
- Provide three-year projections, drivers, scenarios, capex/working-capital assumptions and financing plan.
| date | round or event | amount or valuation | lead or participants | verification status | source |
|---|---|---|---|---|---|
| 2025-01-23 | Unicorn-list valuation anchor | $1.8B | Lightspeed Venture Partners, General Catalyst | verified from market database; financing documents private | CB Insights unicorn list |
| Current | Current cash, debt and runway | not_publicly_verifiable | Company finance team / investors | not_publicly_verifiable | Data-room request |
I.C Capital Structure
partially verified confidence: medium
Public investor/valuation evidence exists, but fully diluted ownership, options, warrants, notes, debt and preferences are not public.
Evidence gaps
- Current cap table and financing documents are private.
Hidden risks
- R-002 remains open until private diligence closes this section.
Follow-up questions
- Provide fully diluted cap table, debt schedule, warrants/options/SAFEs and liquidation waterfall.
| stakeholder or instrument | public position | verification status | diligence caveat |
|---|---|---|---|
| Select investors | Lightspeed Venture Partners, General Catalyst | verified from CB Insights list | Ownership percentages, preferences and side letters are not public. |
| Common/options/warrants/SAFEs/debt | not_publicly_verifiable | not_publicly_verifiable | Requires fully diluted cap table and financing documents. |
| Eligibility status | Appears as active private unicorn candidate in reviewed public sources. | partially_verified | Confirm no IPO/acquisition/shutdown and verify corporate status with counsel. |
I.D Other financial information
not publicly verifiable confidence: low
Tax positions, accounting policy detail and financing-history terms require private records.
Evidence gaps
- Tax, accounting and financing history documents are private.
Hidden risks
- R-001 remains open until private diligence closes this section.
- R-002 remains open until private diligence closes this section.
Follow-up questions
- Provide tax memos, accounting policies and complete financing history.
02Products
Neko Health has an active public product surface in Preventive health checks, full-body scanning, clinical operations, and AI-enabled health data analysis, but roadmap, quality, adoption and profitability require private validation.
II.A Description of each product
partially verified confidence: medium
Public product materials support an active product/service surface, but growth, market share, cost structure, roadmap and profitability need validation.
Evidence gaps
- Usage, roadmap, reliability, market share and product gross margin are private.
Hidden risks
- R-005 remains open until private diligence closes this section.
Follow-up questions
- Provide product usage, roadmap, technical KPIs, gross margin and customer feedback.
| product | audience | public evidence | verification status |
|---|---|---|---|
| Neko full-body health scan | Consumers/patients seeking preventive health checks | Public homepage markets a thorough health check, instant results and doctor time. | partially_verified from public materials; private usage and economics needed |
| Longitudinal health data tracking | Repeat consumers and clinicians | Homepage describes tracking millions of data points and building on annual data. | partially_verified from public materials; private usage and economics needed |
| Doctor-led preventive care model | Clinic-based patient care | Public evidence indicates doctor-led care; clinical protocols and outcomes require diligence. | partially_verified from public materials; private usage and economics needed |
| package or metric | public signal | verification status | follow up |
|---|---|---|---|
| Published pricing or booking/demo path | Public homepage pricing discloses a GBP 299 scan price, but utilization, margin, payor mix, refunds and expansion economics are not public. | partially_verified | Request actual contracted pricing, discounting, utilization and revenue by product. |
| Competitor pricing benchmark | Not benchmarked from reliable public data in this workflow. | not_publicly_verifiable | Run competitive pricing study and win/loss interviews. |
03Customer Information
Public customer, buyer or partner signals exist, but revenue concentration, contract terms, renewal quality and satisfaction are not publicly verifiable.
III.A Top customers by application
partially verified confidence: medium
Public customer or demand signals exist, but a top-customer list and revenue by application are private.
Evidence gaps
- Top 15 customers and purchase history are private.
Hidden risks
- R-003 remains open until private diligence closes this section.
Follow-up questions
- Provide top-customer schedule by revenue/application and reference-call permissions.
| customer or segment | use case | public evidence | revenue concentration gap |
|---|---|---|---|
| Individual scan customers | Direct-to-consumer preventive health | Public booking/pricing supports a consumer clinic model; utilization and repeat rates are private. | Revenue, margin, renewal and satisfaction not public. |
| Stockholm / London clinic users | Local clinic demand | Public profile evidence references operations in Stockholm and London as of 2024. | Revenue, margin, renewal and satisfaction not public. |
| Future expansion markets | International consumers | Public sources indicate expansion ambition, but regulatory approvals and launch economics need validation. | Revenue, margin, renewal and satisfaction not public. |
III.B Strategic relationships
partially verified confidence: medium
Public partner or ecosystem signals create diligence leads, but economics and contractual commitments are private.
Evidence gaps
- Revenue contribution, exclusivity and marketing terms are private.
Follow-up questions
- Provide partner agreements and partner-sourced pipeline/revenue.
| partner | relationship type | public evidence | gap |
|---|---|---|---|
| Clinical staff and doctors | Care delivery | Doctor-led model requires licensed staffing and clinical QA; staffing contracts are private. | Contract terms, exclusivity, economics and termination rights not public. |
| Technology and sensor suppliers | Scanning hardware/software supply chain | Supplier identity, exclusivity and uptime commitments are not public. | Contract terms, exclusivity, economics and termination rights not public. |
III.C Revenue by customer
not publicly verifiable confidence: low
Revenue by customer and any 5%+ concentration cannot be verified publicly.
Evidence gaps
- Customer revenue concentration is private.
Hidden risks
- R-003 remains open until private diligence closes this section.
Follow-up questions
- Provide revenue by customer, NRR/GRR, churn and renewal status.
III.D Significant relationships severed within the last two years
not publicly verifiable confidence: low
No public evidence reviewed provides a complete list of severed material relationships.
Evidence gaps
- Lost customer/partner/supplier schedule is private.
Follow-up questions
- Provide churn/lost-logo list and severed strategic relationships for two years.
III.E Top suppliers
not publicly verifiable confidence: low
Top suppliers and purchase amounts are not public.
Evidence gaps
- Supplier contracts and concentration are private.
Hidden risks
- R-008 remains open until private diligence closes this section.
Follow-up questions
- Provide supplier schedule, spend concentration, SLAs and termination rights.
| supplier or dependency | role | public evidence | risk |
|---|---|---|---|
| Core technology / infrastructure suppliers | Product delivery | Specific supplier contracts are not public. | Operational dependency and concentration risk require contract review. |
| Customer-facing support / implementation resources | Adoption and retention | Public GTM is consumer/patient booking for scans, clinic-based care, repeat annual tracking, and geographic expansion from Sweden/UK markets. | Service quality, SLAs and support load not public. |
04Competition
Public positioning implies differentiated value, but competitive durability must be tested through win/loss, pricing, product and buyer-reference diligence.
IV.A Competitive landscape by market segment
inconclusive confidence: medium
Public positioning identifies likely competitive axes, but market share, win/loss and pricing power are unresolved.
Evidence gaps
- Market share and buyer preference data are not public.
Hidden risks
- R-004 remains open until private diligence closes this section.
Follow-up questions
- Provide win/loss, pipeline displacement, pricing benchmarks and customer references.
| competitor | segment | product overlap | diligence focus | source basis |
|---|---|---|---|---|
| Prenuvo | Whole-body MRI screening | Competes for preventive scan demand and clinical-outcome credibility. | EC-011 | Analyst synthesis from public target positioning; benchmark externally. |
| Ezra | AI-assisted cancer screening / imaging | Competes for preventive imaging consumers and physician trust. | EC-011 | Analyst synthesis from public target positioning; benchmark externally. |
| Traditional private health assessments | Clinic-based preventive checkups | Competes on clinician trust, price, convenience and diagnostic scope. | EC-011 | Analyst synthesis from public target positioning; benchmark externally. |
| Public healthcare systems | Primary care and screening pathways | May influence willingness to pay and referral/clinical standards. | EC-011 | Analyst synthesis from public target positioning; benchmark externally. |
| axis | target public position | risk if unproven | diligence request |
|---|---|---|---|
| Product value / differentiation | The homepage describes tracking millions of data points in a few minutes and a doctor-led model of care. | Buyer substitutes incumbent or lower-cost alternatives. | Benchmark against top competitors and collect win/loss proof. |
| Trust, compliance and reliability | Neko operates in healthcare settings, making clinical quality, medical-device classification, privacy and doctor-led-care controls central diligence areas. | Enterprise/regulated buyers may block adoption or renewal. | Review compliance reports, incident history and customer security questionnaires. |
05Marketing, Sales, and Distribution
Public GTM surfaces are visible, but funnel conversion, sales efficiency, channel mix, CAC and payback are private.
V.A Strategy and implementation
partially verified confidence: medium
Public GTM surfaces are observable, but implementation effectiveness is not public.
Evidence gaps
- Channel mix and CAC/payback are private.
Hidden risks
- R-004 remains open until private diligence closes this section.
Follow-up questions
- Provide GTM plan, channel performance, pipeline conversion and budget.
| channel | region or segment | public evidence | private kpi needed |
|---|---|---|---|
| Company website / direct conversion | Sweden and United Kingdom with announced international expansion signals | Public GTM is consumer/patient booking for scans, clinic-based care, repeat annual tracking, and geographic expansion from Sweden/UK markets. | Pipeline, conversion, CAC, payback and revenue by channel. |
| Partners / ecosystem / referrals | Publicly indicated partner or customer ecosystem | The public booking flow markets consumer preventive health scans; top customer concentration is not applicable in the same way as B2B but clinic utilization is private. | Partner-sourced pipeline, attach rate, churn and contract terms. |
V.B Major Customers
partially verified confidence: medium
Public customer signals do not establish major-customer trend quality.
Evidence gaps
- Major-customer pipeline and expansion opportunities are private.
Hidden risks
- R-003 remains open until private diligence closes this section.
Follow-up questions
- Provide account plans, expansion pipeline, renewal risks and customer references.
| signal | observed public evidence | verification status | risk or gap |
|---|---|---|---|
| Product positioning | Neko describes a thorough health check with instant results and unrushed time with a doctor for GBP 299. | verified as company claim | Needs independent buyer validation. |
| Customer/partner proof routes | The public booking flow markets consumer preventive health scans; top customer concentration is not applicable in the same way as B2B but clinic utilization is private. | partially_verified | Needs reference calls and cohort data. |
| Content, demo, booking or support resources | Public GTM is consumer/patient booking for scans, clinic-based care, repeat annual tracking, and geographic expansion from Sweden/UK markets. | verified as public GTM surface | Needs funnel conversion and sales-productivity data. |
V.C Principal avenues for generating new business
partially verified confidence: medium
Public sources indicate routes to demand, but lead source conversion is private.
Evidence gaps
- Lead-source attribution and conversion are private.
Follow-up questions
- Provide lead-source funnel and cohort conversion.
V.D Sales force productivity model
not publicly verifiable confidence: low
Sales compensation, quota, productivity, sales cycle and hiring plan are not public.
Evidence gaps
- Sales force productivity model is private.
Follow-up questions
- Provide sales comp, quotas, attainment, ramp and sales-cycle analysis.
V.E Ability to implement marketing plan with current and projected budgets
not publicly verifiable confidence: low
Budget sufficiency for the marketing plan cannot be verified publicly.
Evidence gaps
- Marketing budget and plan are private.
Follow-up questions
- Provide marketing budget, ROI, hiring plan and sensitivity analysis.
06Research and Development
Technology and R&D claims are central to the thesis, yet independent benchmarks, roadmap, security/quality artifacts and R&D staffing data are not public.
VI.A Description of R&D organization
partially verified confidence: medium
Public technology/team signals exist, but R&D organization, key personnel, budget and ownership are not fully verifiable.
Evidence gaps
- R&D org chart and budget are private.
Hidden risks
- R-005 remains open until private diligence closes this section.
- R-007 remains open until private diligence closes this section.
Follow-up questions
- Provide R&D org chart, roadmap ownership, budget and key-person retention.
| name or role | role | source status | diligence note |
|---|---|---|---|
| Daniel Ek | Co-founder / chair | Public profile evidence | Public profile says Ek co-founded Neko Health in 2018 and chairs the company. |
| Hjalmar Nilsonne | Co-founder / operating leadership | Public profile evidence | Public profile says engineer Hjalmar Nilsonne co-founded Neko Health with Ek. |
| Clinical leadership | Medical operations | Not fully verified from extracted public sources | Request medical director, QA, licensing and clinical governance documentation. |
VI.B New Product Pipeline
partially verified confidence: medium
Public product materials imply active development, but new product timing, development cost and critical technology risk are private.
Evidence gaps
- Pipeline timing and development cost are private.
Hidden risks
- R-005 remains open until private diligence closes this section.
Follow-up questions
- Provide roadmap, milestones, technical-risk register and cost-to-complete.
| project or area | status | public evidence | verification |
|---|---|---|---|
| Core platform roadmap | Active public product surface | The homepage describes tracking millions of data points in a few minutes and a doctor-led model of care. | Partially verified; roadmap timing and R&D budget private. |
| Security / compliance / quality roadmap | Diligence request | Neko operates in healthcare settings, making clinical quality, medical-device classification, privacy and doctor-led-care controls central diligence areas. | Not publicly verifiable without controls, audit and incident artifacts. |
07Management and Personnel
Public team evidence is limited relative to transaction diligence needs; org structure, retention, compensation and key-person risk remain open.
VII.A Organization Chart
not publicly verifiable confidence: low
A complete organization chart is not public.
Evidence gaps
- Org chart and reporting lines are private.
Hidden risks
- R-007 remains open until private diligence closes this section.
Follow-up questions
- Provide current and projected org chart.
VII.B Historical and projected headcount by function and location
not publicly verifiable confidence: low
Historical/projected headcount by function and location is not public.
Evidence gaps
- HRIS exports and headcount plan are private.
Hidden risks
- R-007 remains open until private diligence closes this section.
Follow-up questions
- Provide headcount by function/location, hiring plan and attrition.
| function or region | public signal | verification status | diligence request |
|---|---|---|---|
| Current headcount by function and location | Not disclosed in fetched public sources. | not_publicly_verifiable | HRIS export by department, geography, tenure and employment type. |
| Leadership / technical staffing | Public profile evidence says Daniel Ek co-founded Neko Health in 2018 with engineer Hjalmar Nilsonne; Ek chairs the company and is not involved in daily operations. | partially_verified | Current org chart, key-person risk, attrition and retention plan. |
VII.C Senior management biographies
partially verified confidence: medium
Limited public leadership evidence exists, but complete biographies and tenure verification require company records.
Evidence gaps
- Management biographies and background checks are private.
Hidden risks
- R-007 remains open until private diligence closes this section.
Follow-up questions
- Provide leadership bios, references, background checks and board/advisor roster.
| person or role | title or function | public evidence | gap |
|---|---|---|---|
| Daniel Ek | Co-founder / chair | Public profile evidence | Public profile says Ek co-founded Neko Health in 2018 and chairs the company. |
| Hjalmar Nilsonne | Co-founder / operating leadership | Public profile evidence | Public profile says engineer Hjalmar Nilsonne co-founded Neko Health with Ek. |
| Clinical leadership | Medical operations | Not fully verified from extracted public sources | Request medical director, QA, licensing and clinical governance documentation. |
VII.D Compensation arrangements
not publicly verifiable confidence: low
Employment agreements, compensation and benefits are not public.
Evidence gaps
- Compensation arrangements are private.
Hidden risks
- R-007 remains open until private diligence closes this section.
Follow-up questions
- Provide employment agreements, benefit plans and compensation bands.
VII.E Incentive stock plans
not publicly verifiable confidence: low
Incentive stock plan terms and grants are not public.
Evidence gaps
- Equity plan and option grants are private.
Follow-up questions
- Provide equity plan, option ledger and vesting schedules.
VII.F Significant employee relations problems, past or present
not publicly verifiable confidence: low
Significant employee-relations problems cannot be ruled in or out from this public review.
Evidence gaps
- Employee-relations matters are private.
Follow-up questions
- Provide HR complaints, investigations and settlement schedule.
VII.G Personnel Turnover
not publicly verifiable confidence: low
Personnel turnover data for the last two years is not public.
Evidence gaps
- Turnover and retention metrics are private.
Hidden risks
- R-007 remains open until private diligence closes this section.
Follow-up questions
- Provide attrition by function/location, regretted loss and retention plan.
08Legal and Related Matters
Legal, regulatory, IP, contract, insurance and docket diligence cannot be completed from public materials and should be prioritized before investment reliance.
VIII.A Pending lawsuits against the Company
unverified confidence: low
No comprehensive public docket search artifact was available in this workflow.
Evidence gaps
- Pending litigation against the company requires counsel search.
Follow-up questions
- Provide litigation schedule and counsel docket search.
VIII.B Pending lawsuits initiated by Company
unverified confidence: low
No comprehensive public docket search artifact was available for company-initiated lawsuits.
Evidence gaps
- Claims initiated by company require counsel search.
Follow-up questions
- Provide litigation/IP enforcement schedule.
VIII.C Environmental and employee safety issues and liabilities
partially verified confidence: medium
Public business model suggests safety/environmental/employee-safety diligence themes, but records are private.
Evidence gaps
- Safety and environmental records are private.
Hidden risks
- R-006 remains open until private diligence closes this section.
Follow-up questions
- Provide safety policies, incident logs and regulatory correspondence.
VIII.D Material patents, copyrights, licenses, and trademarks
not publicly verifiable confidence: low
Material patents, trademarks, licenses, copyrights and IP assignments were not comprehensively verified.
Evidence gaps
- IP portfolio and assignments are private or require specialist search.
Hidden risks
- R-006 remains open until private diligence closes this section.
Follow-up questions
- Provide IP schedule, invention assignments, licenses and open-source review.
| artifact | public signal | verification status | priority |
|---|---|---|---|
| Patents, trademarks, copyrights, licenses and IP assignments | Not comprehensively searched or verified in this public-source workflow. | not_publicly_verifiable | high |
| Material customer/supplier contracts and insurance | Contract schedules and insurance policies not public. | not_publicly_verifiable | high |
VIII.E Insurance coverage and material exposures
not publicly verifiable confidence: low
Insurance coverage and material exposures are not public.
Evidence gaps
- Insurance policies and claims are private.
Follow-up questions
- Provide insurance policies, claims history and coverage opinions.
VIII.F Material contracts
not publicly verifiable confidence: low
Material customer, supplier, partner and financing contracts are not public.
Evidence gaps
- Material contracts are private.
Hidden risks
- R-006 remains open until private diligence closes this section.
- R-008 remains open until private diligence closes this section.
Follow-up questions
- Provide material contract schedule and change-of-control analysis.
VIII.G Regulatory agency problems
partially verified confidence: medium
Public sources identify regulatory themes, but agency history and correspondence are not public.
Evidence gaps
- Regulatory agency matters require counsel/company confirmation.
Hidden risks
- R-006 remains open until private diligence closes this section.
Follow-up questions
- Provide regulatory correspondence, audits, complaints and remediation plans.
| matter type | public evidence | status | diligence request |
|---|---|---|---|
| Pending lawsuits against company | No comprehensive docket search artifact available in this workflow. | unverified | Counsel-run docket search and litigation schedule. |
| Regulatory/privacy/compliance exposure | Neko operates in healthcare settings, making clinical quality, medical-device classification, privacy and doctor-led-care controls central diligence areas. | partially_verified thematic exposure | Regulatory correspondence, policies, audits, insurance and incident history. |
Evidence
| ID | Claim | Status | Sources |
|---|---|---|---|
| EC-001 | Neko Health appears on the fetched current unicorn list at $1.8B. | verified high | SRC-001 |
| EC-002 | Neko Health publicly markets an active product or service surface. | verified medium | SRC-002 |
| EC-003 | Neko Health has a public product/capability matrix relevant to its sector. | verified medium | SRC-003 |
| EC-004 | Neko Health shows a public monetization or pricing signal but not realized economics. | partially verified medium | SRC-002SRC-003 |
| EC-005 | Neko Health has public customer, buyer, partner or demand-channel signals. | partially verified medium | SRC-004 |
| EC-006 | Neko Health's public materials include technology or AI-related differentiation claims. | partially verified medium | SRC-002SRC-003 |
| EC-007 | Neko Health has observable public go-to-market surfaces. | verified medium | SRC-002SRC-004 |
| EC-008 | Neko Health has limited public team or founder evidence available from fetched public sources. | partially verified medium | SRC-002SRC-006 |
| EC-009 | Neko Health's regulatory/legal posture cannot be fully verified from public sources. | partially verified medium | SRC-002SRC-004 |
| EC-010 | Neko Health's core private diligence records were not publicly available. | not publicly verifiable high | SRC-001SRC-002SRC-003SRC-004 |
| EC-011 | Neko Health operates in a competitive market where public positioning must be benchmarked. | inconclusive medium | SRC-002SRC-003SRC-004 |
| EC-012 | Neko Health passed public-source eligibility screening as an active private unicorn candidate. | partially verified medium | SRC-001SRC-002 |
| ID | Publisher | Title | Accessed |
|---|---|---|---|
| SRC-001 | CB Insights | CB Insights complete list of unicorn companies | 2026-05-25 |
| SRC-002 | primary_company_source | Neko Health homepage | 2026-05-25 |
| SRC-003 | primary_company_source | Neko Health homepage and Daniel Ek public profile | 2026-05-25 |
| SRC-004 | primary_company_source | Neko Health homepage | 2026-05-25 |
| SRC-005 | other | Fetched public-source research notes for random unicorn selection | 2026-05-25 |
| SRC-006 | independent_news | Daniel Ek public profile referencing Neko Health | 2026-05-25 |
| SRC-007 | primary_company_source | Neko Health homepage | 2026-05-25 |
Disclaimer
This report is a public-evidence diligence snapshot, not investment advice. Important financial, legal, technical, and contractual facts remain non-public and should be verified directly with management and primary documents before any investment decision.